Direct High Affinity Modulation of Connexin Channel Activity by Cyclic Nucleotides*

Carville G. BevansDagger and Andrew L. Harris§

From the Thomas C. Jenkins Department of Biophysics, The Johns Hopkins University, Baltimore, Maryland 21218

    ABSTRACT
Top
Abstract
Introduction
References

Connexin channels mediate molecular communication between cells. However, positive identification of biological ligands that directly and noncovalently modulate their activity has been elusive. This study demonstrates a high affinity inhibition of connexin channels by the purine cyclic monophosphates cAMP and cGMP. Purified homomeric connexin-32 and heteromeric connexin-32/connexin-26 channels were inhibited by exposure to nanomolar levels of the nucleotides prior to incorporation into membranes. Access to the site of action, or affinity for the nucleotides, was greatly reduced following incorporation of the connexin channels into membranes, where inhibition required millimolar concentrations of the nucleotides. The high affinity inhibition did not occur with similar concentrations of AMP, ADP, ATP, cTMP, or cCMP. This is the first report of a direct ligand effect on connexin channel function. The high affinity and specificity of the inhibition suggest a biological role in control of connexin channels and also may lead to the application of affinity reagents to study of connexin channel structure-function.

    INTRODUCTION
Top
Abstract
Introduction
References

The gating of connexin channels by ligands is a key uncharacterized element of intercellular signaling. Connexin channels mediate intercellular molecular signaling that is important in developmental and physiological contexts (1-3). However, the biological ligands that directly regulate connexin channel activity have been difficult to positively identify. Direct action on connexin channels is difficult to establish due to the intercellular channel structure and the cytoplasmic location of channel modulatory sites.

Junctional coupling between cells can be reduced by exposure of cells to various compounds (reviewed in Refs. 4-6). In some cases, it is known that the effects on junctional conductance are not due to direct action of the applied compounds on the connexin channels, but to cytoplasmic mediators (e.g. kinases, cf. Ref. 7). However, in most cases the mechanism of action, and whether it is direct or indirect, is not known. The most well documented direct modulators of connexin channels are voltage (cf. Refs. 8-11) and phosphorylation (7, 12, 13), which can each alter substate occupancy of certain connexins. However, voltage is not likely to be a physiologically important regulator except in specific locations in excitable tissues. Cytoplasmic acidification causes most cells to uncouple, but this may not be a direct effect (14-16).

The identification of ligands of connexin channels is important for understanding the physiology of intercellular signaling. It is also important because it can lead to the use of affinity reagents to explore the structure-function of connexins. The biophysical study of connexin channels has been hindered by the absence of specific affinity reagents or toxins. Such agents (e.g. tetrodotoxin and charybdotoxin) have been vitally important in elucidating molecular mechanisms of other channels (17, 18)

The studies reported here utilize connexin channels composed of connexin-32 (Cx32)1 and connexin-26 (Cx26) purified from native tissues by immunoaffinity chromatography. These two connexins have a high degree of sequence identity (62%) and are often found in the same cells and in the same junctional plaques (19-23). Their close association implies a functional and/or structural relationship in situ.

Compounds that alter junctional coupling when applied to cells were tested for efficacy in a reconstituted system. A high affinity, modulatory action of purine cyclic monophosphates, but not other nucleotides, on connexin channel activity was discovered. The chemical specificity and nanomolar affinity suggest a biological role. Preliminary reports of this work have appeared in abstract form (24-27).

    EXPERIMENTAL PROCEDURES

Materials-- Egg phosphatidylcholine, bovine phosphatidylserine, azolectin (soybean L-phosphatidylcholine), and lissamine rhodamine B-labeled phosphatidylethanolamine were purchased from Avanti Polar Lipids. Tween 20, nitro blue tetrazolium, and diisopropylfluorophosphate were obtained from Sigma. N-Octyl-D-glucopyranoside (octylglucoside) was from Calbiochem. Bio-Gel (A-0.5 m; exclusion limit, 500,000 Da) was purchased from Bio-Rad. Alkaline phosphatase-conjugated goat anti-mouse IgG and 5-bromo-4-chloro-3-indolyl-phosphate were purchased from Boehringer Mannheim Biochemicals. CNBr-activated Sepharose beads were obtained from Amersham Pharmacia Biotech and Immobilon-P transfer membrane from Millipore. Rats and mice were obtained from Taconic. Use and care of animals was according to institutional guidelines.

Immunopurification of Connexin Proteins-- Connexin was affinity-purified from an octylglucoside-solubilized crude membrane fraction of rat or mouse liver using a monoclonal antibody against Cx32 as described in Refs. 28 and 29, with the modification that 5 mM EGTA was included in the homogenization and phosphate buffers.

Gel Electrophoresis, Protein Blots, and Immunoblots-- Samples of liposomes for gel electrophoresis were prepared by extracting lipids in absolute methanol and washing and concentrating the protein on a 30-kDa cutoff filter cartridge (Ultrafree, Millipore Corp.). Gel electrophoresis, blotting, and staining of blots were carried out as described in Ref. 29.

Antibodies-- The monoclonal antibody (M12.13) used in the immunoaffinity purification and for specific staining of connexin-32 on Western blots is directed against a cytoplasmic domain of Cx32 (30).

Reconstitution of Purified Connexin into Unilamellar Phospholipid Liposomes-- Liposome formation and protein incorporation followed the protocol of Mimms et al. (31) as modified by Harris et al. (32) and Rhee et al. (28), and summarized in the companion paper (33). To ensure that the potential modulatory agents were available without dilution to the connexin until liposome formation, a 4 ml volume of buffer containing the agents was loaded onto the gel-filtration column before the liposome-forming solution was loaded.

Transport-specific Fractionation (TSF)-- The procedure used to fractionate liposomes into two populations based on sucrose permeability is described and fully characterized in Harris et al. (32, 34) and Rhee et al. (28) and summarized in the companion paper (33). Liposomes containing functional channels are separated from liposomes without functional channels by TSF achieved by centrifugation through an iso-osmotic density gradient formed by urea and sucrose solutions. Equilibration of extraliposomal and intraliposomal osmolytes is rapid (milliseconds for these 900-Å diameter liposomes). Therefore, even a channel that opens only infrequently for brief times will mediate full exchange of osmolytes and cause liposome movement to the characteristic lower position. The assay will not detect the activity of channels with Po less than 0.001, so this is effectively an all-or-none assay for channel function based on urea/sucrose permeability.

Data Analysis-- The studies of cyclic nucleotide binding involve exposure of solubilized connexin channels to several ligand concentrations. The ligand is essentially locked in place by incorporation of the connexin into liposome membrane as detergent diffuses away during reconstitution, and its effect is assessed as a change in channel activity relative to controls without ligand. Therefore the channel activity gives a quantitative assessment of the fraction of channels to which ligand is bound at the moment of reconstitution in membranes---it is a "snapshot" of binding. In this way, it is formally analogous to a standard binding assay in which one assesses the average fraction of receptors occupied for a given concentration of ligand. The process is irreversible after reconstitution up to the lifetime of functional channels in the liposomes (~4 weeks).

Rather than looking at the aggregate response of a population of receptors while association-dissociation reactions take place, this assay captures those associations at a given instant. Thus, an irreversible reaction (incorporation into a bilayer) is used to freeze a reversible reaction (ligand binding) under steady-state conditions.

For each preparation of connexin, the percentage of liposomes in the lower band of TSF data was normalized to the maximum value obtained for that preparation. This enabled comparison of modulatory effects across reconstitutions that produced different amounts of channel activity (fractions of liposomes with functional channels). Where several preparations were used, normalized data sets were combined for calculation of means and standard errors.

Previous work with the TSF system suggested that the channels distribute among the liposomes in a manner described by the Poisson distribution (28). For a given protein-lipid ratio (lambda ) in the liposomes, a Poisson distribution accounts for the fraction of the liposomes that have functional channels. A statistical method was used to correct for the fraction of liposomes that contained more than one channel (described in the companion paper (33)). This calculation compensates for the underestimate of the effect of a test compound introduced by some of liposomes containing more than one channel, transforming the fraction of permeable liposomes in a population to accurately reflect discrete single channel activities.

    RESULTS

Connexin was immunopurified from rodent liver using a monoclonal antibody that recognizes connexin-32. Previous biochemical and functional studies have characterized connexin purified in this way from rat liver as homomeric Cx32 hemichannels, and that from mouse liver as heteromeric Cx32/Cx26 hemichannels (28, 29, 35).

The sensitivities of channels formed by Cx32 and Cx32/Cx26 to several agents were explored and compared by transport-specific fractionation (TSF) of liposomes. TSF has been well characterized (32, 34, 36) and effectively used in studies of channel permeability (28, 29, 37). Purified connexin is incorporated into unilamellar liposomes by gel filtration of a mixture of octylglucoside-solubilized connexin and lipid. TSF fractionates the liposomes on the basis of permeation of osmolytes (urea and sucrose) through the reconstituted channels. Specifically, it employs buoyant density sedimentation to separate into distinct bands liposomes with open channels permeable to urea and sucrose from liposomes that are without such channels. Liposomes that do not contain open connexin channels (i.e., are not permeable to urea and sucrose) migrate to an equilibrium position in the upper part of the gradient. For liposomes that contain open connexin channels, the osmolytes exchange through the channels and the liposomes migrate to a lower position determined only by lipid density. Any significant channel open probability (Po) results in sufficient osmolyte exchange to cause the required change in density. The TSF is therefore an all-or-none assay of per-liposome channel activity.

Effects of test compounds on channel activity were assessed by exposing connexin or connexin-containing liposomes to the compounds prior to or during a TSF spin. Effects on channel activity were quantified as changes in the fraction of liposomes in the lower band relative to that for connexin or liposomes not exposed to the test compound.

The fractional change in distribution of liposomes between the two bands is a quantitative measure of the fractional change in activity of the population of the channels. The change in liposome density can result from brief channel openings, so only when Po changes above or below a low threshold value are changes in channel activity detected by TSF.

Many Compounds That Affect Junctional Communication in Cells Do Not Have Effects on Connexin Channels in the TSF System-- In initial studies, the effects of test compounds were assessed by including them in the TSF solutions. The results are for both homomeric Cx32 channels and heteromeric Cx32/Cx26 channels, except where otherwise indicated.

Table I lists compounds that can affect junctional ionic current or dye transfer when applied to cells but that were without effect in this system. Tables II, III, and IV list additional compounds that were also without detectable effect. Absence of effect indicates that the actions of a compound on connexin channels either (a) are not direct, (b) are not dramatic enough to be detected by TSF, or (c) require the intercellular channel structure (two end-to-end hexameric hemichannels).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Compounds affecting junctional coupling in cells that did not have effects on connexin channel activity in the TSF system

                              
View this table:
[in this window]
[in a new window]
 
Table II
Compounds that inhibit other ion channels that were without effect on connexin channels in the TSF system

                              
View this table:
[in this window]
[in a new window]
 
Table III
Divalent ions without effect on connexin channels in the TSF system

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Miscellaneous compounds without effect on connexin channels in the TSF system

However, positive findings in this system indicate dramatic effects on channel activity. When applied at 10 mM, but not 1 mM, to reconstituted hemichannels, cAMP inhibited channel activity (Fig. 1). Activity was not affected by 10 mM adenine or adenosine. By cytoplasmic standards, 10 mM is a high concentration of cAMP, so a sensitivity in this range is not likely to be biological relevant. We speculated that an apparent low affinity for cAMP could arise from restricted accessibility to a high affinity site. This could occur if the binding site were partially obscured by membrane lipids or if the reconstituted channel was only rarely in a conformation that enabled access to the site.


View larger version (84K):
[in this window]
[in a new window]
 
Fig. 1.   TSF gradients showing inhibition of channel activity by cAMP. The left tube shows separation of connexin-containing liposomes by TSF into two populations: one composed of liposomes without functional channels (upper bands, upper arrows) and one composed of liposomes with functional channels (lower band, lower arrow). The liposomes without open channels come to a position in the upper part of the tube because the more dense lipid is buoyed up by the entrapped urea solution of lighter density. Liposomes with open channels equilibrate the intraliposomal solution with the external solution and move to a lower position determined solely by lipid density. Liposome membranes contain a trace amount of rhodamine-PE. The right tube shows the effect on the same population of liposomes of 10 mM cAMP in the gradient. Channel activity was completely inhibited, resulting in only a single band, at the upper position.

High Affinity Inhibition of Solubilized Connexin Channels by cAMP or cGMP-- A high affinity interaction between cyclic nucleotides and connexin was established by studies in which connexin in lipid-detergent micelles was exposed to the nucleotides. In pilot studies of connexin channel permeation, connexin channels were exposed to low amounts of cAMP or cGMP as permeability tracers in the presence of detergent during liposome formation. Even though the nucleotides were present at only micromolar levels, channel activity after reconstitution was completely inhibited. This surprising effect was investigated further: immunopurified connexin was exposed to nucleotides while in detergent, then incorporated into liposomes, and channel activity was assessed.

Exposure of purified connexin to as little as 1.5 nM cAMP or cGMP completely eliminated the channel activity of subsequently reconstituted Cx32 or Cx32/Cx26 channels. This inhibition was not reversible by increase of the salt in the TSF gradients to 100 mM, change of the TSF gradient pH to 5 or 9, or by omitting the nucleotides from the TSF gradient. Western blots established that the presence of cyclic nucleotides during reconstitution had no effect on incorporation of connexin into liposomes (Fig. 2). The inhibition of channel activity is not due to the action of cyclic nucleotide-dependent protein kinase as there was none present, nor was there ATP or divalent cations.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   Western blots showing no effect of exposure to cAMP during reconstitution on subsequent incorporation of connexin into liposomes. A, protein incorporated into liposomes without exposure to cAMP. B, protein incorporated into liposomes in the presence of 100 µM cAMP. Both lanes were immunostained with a monoclonal antibody against Cx32 (30) and developed with alkaline phosphatase. Exposure of the connexin to a cAMP concentration 5 orders of magnitude greater than that required to inhibit channel activity (1 nM) did not affect incorporation of the connexin into liposome membrane.

No effect was seen with 1.5 nM AMP, ADP, ATP, cTMP, or cCMP. Therefore this high affinity effect was specific for cyclic purine monophosphates (cPMPs). This is the first evidence of a modulatory high affinity binding site for a second messenger on connexin channels.

Dose-response data of the cPMP effect were obtained by performing reconstitutions using aliquots from a detergent-solubilized lipid and connexin mixture containing different concentrations of cyclic nucleotide (either cAMP or cGMP). The Hill equation was fitted to the dose/response data (Fig. 3). Homomeric Cx32 showed essentially identical high affinity inhibition by both cAMP (Kd = 0.106 nM; nHill = 2.1) and cGMP (Kd = 0.108 nM; nHill = 1.5). For heteromeric Cx32/Cx26 channels, cAMP effects were higher affinity and somewhat less cooperative (Kd = 0.054 nM; nHill = 1.1) than cGMP effects (Kd = 0.15 nM; nHill = 1.6). The homomeric Cx32 channels have affinities for the two cyclic nucleotides intermediate to those of the Cx32/Cx26 channels.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Dose-response relations for cAMP and cGMP. Connexin was reconstituted in a range of concentrations of cAMP (triangles) or cGMP (circles). Nucleotide was not present in the TSF gradients. Data were fit using the Hill equation. Bars are S.E. A, homomeric Cx32 channels had essentially identical responses to cAMP and to cGMP. B, heteromeric Cx32/Cx26 channels were more sensitive to cAMP than to cGMP. For both types of connexin channels, binding of nucleotide inhibited subsequent channel activity and appears to involve more than one binding site per channel.

Exposure to 1.5 nM cyclic nucleotide fluorescent analogs 1,N6-etheno-cAMP and 2'-(N-methylanthraniloyl)-cGMP or to the photoaffinity reagent 8-azido-cAMP during detergent solubilization also completely inhibited both homomeric Cx32 and heteromeric Cx32/Cx26 channel activity.

Permeabilization of the liposome membranes by exposure to 5% Me2SO or to octylglucoside levels below the critical micelle concentration did not reverse the inhibition. Additionally, attempts to induce the inhibition in reconstituted channels not previously exposed to cyclic nucleotide by exposure of the liposomes to 10 µM cAMP or 8-(4-chlorophenylthio)-cAMP (a hydrophobic analog of cAMP) in 5% Me2SO or octylglucoside levels below the critical micelle concentration were not successful.

    DISCUSSION

These experiments demonstrate the existence of a selective, high affinity modulatory site for cyclic purine monophosphates on connexin channels. The site is accessible while the protein is in micelles and/or during its transition from micellar to bilayer environments, and it becomes less accessible following incorporation of the channels into membranes.

The inhibition of channel activity by cPMPs could be achieved by allosteric effects or physical occlusion of the pore. The latter is not likely because cPMPs can permeate reconstituted Cx32 channels (29). The much-reduced sensitivity of reconstituted channels may indicate that after reconstitution the site is accessible only when the protein is in a restricted set of conditions or conformational states. Alternatively, the effects at millimolar levels could be due to a distinct, low affinity site unrelated to the effects at nanomolar levels.

That activity inhibition persists in the absence of free nucleotide after reconstitution suggests that once ligand is bound and the channel is incorporated into a membrane, the ligand is precluded from dissociation. This may occur by conformational changes secondary to binding or to the transition to a membrane environment. Examples of the former include the binding-dependent conformational change that occurs in peptide binding by calmodulin (38, 39) and by the molecular chaperone DnaK (40). Binding at an active site can involve conformational changes that stabilize the bound complex (41, 42) or render it inaccessible to bulk solvent (43). Receptor-ligand complexes can have half-lives of days (44-47). Alternatively, dissociation of ligand may be blocked by membrane lipids, where the bound ligand is shielded from the aqueous phase by the phospholipid bilayer following reconstitution.

Cyclic nucleotides can permeate some junctional channels (48-52), as well as hemichannels (29), so the inhibition at subnanomolar levels may seem paradoxical. However, cytoplasmic concentrations of cyclic nucleotides range between nanomolar and micromolar, well below the millimolar levels required for effects on connexin channels already in membranes.

Homomeric Cx32 and heteromeric Cx32/Cx26 have distinguishable but similar affinities for the nucleotides, suggesting that the binding sites for the nucleotides on the two connexins are different, but not dramatically so. The activity of the cyclic nucleotide analogs may be informative regarding the nature of the binding site. Because 1,N6-etheno-cAMP and 8-azido-cAMP are derivatized on the purine ring, 2'-(N-methylanthraniloyl)-cGMP is derivatized on the ribose sugar, and all three are effective at nanomolar levels, it appears that additions to the 2, 8, N6 and 2'-hydroxyl groups do not preclude steric fit into the putative binding site.

Cyclic nucleotides directly modulate protein function in several systems. The most well known class is the catabolite activator protein (CAP) family of proteins, which includes the Escherichia coli CAP, cyclic-nucleotide dependent protein kinases, and cyclic-nucleotide-gated ion channels (53, 54). However, Cx32 and Cx26 do not contain the amino acid sequences that are strictly conserved at the cyclic nucleotide binding domains of the CAP family. Neither is there obvious sequence similarity with the postulated cGMP binding domain of cGMP-specific phosphodiesterases (55).

Unlike the CAP and phosphodiesterase families of cyclic nucleotide receptors, which have micromolar affinities, the cAR1 and cAR3 chemoattractant receptors of Dictyostelium have nanomolar affinities for cyclic nucleotides (56), in the same range that we determined for connexins, and mediate physiological responses at subnanomolar levels (57). Further analogy with the cAR family is provided by our finding that 2'-(N-methylanthraniloyl)-cGMP is just as effective as cGMP, suggesting that substitutions at the ribose 2'-OH position do not interfere with binding to connexin. An unsubstituted ribose 2'-OH group is required for binding of cGMP by the CAP family of receptors (58) but not for cAR1 (59)

The amino acids involved in the cyclic nucleotide binding to cAR1 have not yet been identified. However, a region of 26 amino acids (148-173), thought to control access to the binding pocket (60, 61), shows ~25% identity and ~60% homology with a region of Cx32 and Cx26 that spans the cytoplasmic loop and the third transmembrane domain. The same level of identity and homology extends through the eight positions N-terminal to this sequence before dropping off. This sequence similarity is only suggestive; further analogy with the cAR family must await positive identification of the relevant amino acids.

<AR><R><C></C><C><UP>    +   ★++  ★</UP></C><C></C><C><UP>     ★   ++    +★     +★     +  ★  ++++</UP></C></R><R><C><UP>Cx26 123–130:</UP></C><C><UP>TQKVRIEG </UP></C><C><UP>131–155:</UP></C><C><UP> SLWWTYTTSIFFRV-IFEAVFMYVFY</UP></C></R><R><C><UP>cAR1 140–147:</UP></C><C><UP>KNTVQFVG</UP></C><C><UP>148–173:</UP></C><C><UP> NWCWIGVSFTGYRFGLFYGPFLFIWA</UP></C></R><R><C><UP>Cx32 22–129:</UP></C><C><UP>RHKVHISG</UP></C><C><UP>130–154:</UP></C><C><UP> TLWWTYVISVVFRL-LFEAVFMYVFY</UP></C></R><R><C></C><C><UP> ++   ★++   ★</UP></C><C></C><C><UP>   ★    ★  +   +★+ ★★   +   ★++++</UP></C></R><R><C></C><C></C><C></C><C><UNL>             </UNL>                    </C></R><R><C></C><C></C><C></C><C><UP>M3 domain of connexin</UP></C></R></AR>
<UP><SC>Sequence</SC> 1. Alignment and homologies were obtained from Align using BLOSUM50. ★, identity; +, homology.</UP>

Hill coefficients of between 1 and 2 for the cPMP effects suggest that there could be two independent binding sites or more than two cooperative sites per channel. Because all six Cx32 subunits comprising a homomeric hemichannel have identical sequences, there are potentially six binding sites per hemichannel. On the other hand, it is conceivable that the sites of action are within the pore and altered by the micelle-membrane transition.

The fact that connexin channels have subnanomolar specific affinities for cAMP and cGMP, and that binding of these cyclic nucleotides closes connexin channels, is likely to be of physiological importance. One possible function is to keep hemichannels closed while they are in Golgi or endoplasmic reticulum membranes. The binding site may be accessible during initial membrane insertion and/or channel assembly, when cytoplasmic cPMPs could bind and thus ensure that connexin hemichannels remain closed during trafficking to the plasma membrane. Docking of apposed hemichannels to form the full intercellular channel could cause dissociation of these nucleotides from connexin channels.

Connexin-32 is co-translationally inserted into endoplasmic reticulum membrane (62, 63). Intriguingly, it has been shown that during co-translational insertion of polytopic membrane proteins, the transmembrane segments inserted through the endoplasmic reticulum membrane are stabilized in a salt-accessible compartment, apparently not interacting directly with lipid (64, 65). Thus, regions of a folded membrane protein that will be later blocked from aqueous access by membrane lipid appear to be transiently accessible to cytoplasmic components.

In view of this, we favor the view that both the micellar environment in our experiments and the partially unfolded state of the protein as it is inserted into a bilayer renders the cPMP site(s) accessible. NMR studies show that nondenaturing detergent such that used in these studies increase molecular motion of and accessibility to protein domains that are exposed to lipid when in bilayers (66, 67). Specifically, there is particularly enhanced accessibility to residues at the membrane-water transition (68, 69). There is evidence that nondenaturing detergents do not fully coat the hydrophobic surfaces of proteins (unlike SDS), leaving a somewhat open structure (70, 71) accessible to small, hydrophilic ligands.

Furthermore, the predicted number of residues for connexin transmembrane helices suggests that the hydrophobic core of the protein is relatively short, composed of five helical turns (28 Å) (72) rather than the six or more typical of channel proteins (73). There may be special lipid requirements for connexin channels in cell membranes to accommodate this. The lipid environment in the present studies is different from that in cell membranes, and may occlude sites that are accessible in them. Differences in the lipid environment may affect accessibility to binding sites, as well as other aspects of channel function (74-78).

This work address two long-standing fundamental issues of connexin channel function. One is the identification and mechanisms of biological ligands that control connexin channel activity. The other is the identification of specific affinity reagents with which to probe the structure-function of connexin channels. These new findings, showing that connexin channels can be directly regulated by a cytoplasmic ligand, are likely to lead to structure-function studies of connexin channels and better understanding of the molecular basis for regulation of intercellular signaling.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant GM36044 and Johns Hopkins University.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Structural Biology, Max-Planck-Institut für Biophysik, Kennedyallee 70, D-60596 Frankfurt am Main, Federal Republic of Germany.

§ To whom correspondence should be addressed: Dept. of Pharmacology & Physiology, New Jersey Medical School, UMDNJ, 185 S. Orange Ave., University Heights, Newark, NJ 07103.

The abbreviations used are: Cx, connexin; CAP, catabolite activator protein; cPMPs, cyclic purine monophosphates cAMP and cGMP; Po, channel open probability; TSF, transport-specific fractionation (of liposomes).
    REFERENCES
Top
Abstract
Introduction
References

  1. Lo, C. W. (1996) J. Bioenerg. Biomembr. 28, 379-385[Medline] [Order article via Infotrieve]
  2. Loewenstein, W. R. (1979) Biochim. Biophys. Acta 560, 1-65[CrossRef][Medline] [Order article via Infotrieve]
  3. Warner, A. E., Guthrie, S. C., and Gilula, N. B. (1984) Nature 311, 127-131[Medline] [Order article via Infotrieve]
  4. Goodenough, D. A., Goliger, J. A., and Paul, D. L. (1996) Annu. Rev. Biochem. 65, 475-502[CrossRef][Medline] [Order article via Infotrieve]
  5. Kumar, N. M., and Gilula, N. B. (1996) Cell 84, 381-388[Medline] [Order article via Infotrieve]
  6. Spray, D. C. (1994) in Molecular Mechanisms of Epithelial Cell Junctions: From Development to Disease (Citi, S., ed), pp. 195-215, R. G. Landes, New York
  7. Sáez, J. C., Spray, D. C., Nairn, A. C., Hertzberg, E. L., Greengard, P., and Bennett, M. V. L. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2473-2477[Abstract]
  8. Spray, D. C., Harris, A. L., and Bennett, M. V. L. (1979) Science 204, 432-434[Medline] [Order article via Infotrieve]
  9. Spray, D. C., Harris, A. L., and Bennett, M. V. L. (1981) J. Gen. Physiol. 77, 77-93[Abstract]
  10. Harris, A. L., Spray, D. C., and Bennett, M. V. L. (1981) J. Gen. Physiol. 77, 95-117[Abstract]
  11. Moreno, A. P., Campos de Carvalho, A. C., Verselis, V. K., Eghbali, B., and Spray, D. C. (1991) Biophys. J. 59, 920-925[Abstract]
  12. Moreno, A. P., Fishman, G. I., and Spray, D. C. (1992) Biophys. J. 62, 51-53[Medline] [Order article via Infotrieve]
  13. Takens-Kwak, B. R., and Jongsma, H. J. (1992) Pflügers Arch. 422, 198-200[Medline] [Order article via Infotrieve]
  14. Nicholson, B. J., Zhou, L., Cao, F., Zhu, H., and Chen, Y. (1998) in Gap Junctions (Werner, R., ed), pp. 3-8, IOS Press, Washington, DC
  15. Bevans, C. G., and Harris, A. L. (1999) J. Biol. Chem. 274, 3711-3719[Abstract/Free Full Text]
  16. Peracchia, C., Lazrak, A., and Peracchia, L. L. (1995) in Handbook of Membrane Channels: Molecular and Cellular Physiology (Peracchia, C., ed), pp. 361-377, Academic Press, San Diego
  17. Miller, C. (1995) Neuron 15, 5-10[Medline] [Order article via Infotrieve]
  18. Strichartz, G. (1987) Annu. Rev. Neurosci. 10, 237-267[CrossRef][Medline] [Order article via Infotrieve]
  19. Zhang, J.-T., and Nicholson, B. J. (1989) J. Cell Biol. 109, 3391-3401[Abstract]
  20. Traub, O., Look, J., Dermietzel, R., Brümmer, F., Hülser, D. F., and Willecke, K. (1989) J. Cell Biol. 108, 1039-1051[Abstract]
  21. Risek, B., Klier, F. G., Phillips, A., Hahn, D. W., and Gilula, N. B. (1995) J. Cell Sci. 108, 1017-1032[Abstract/Free Full Text]
  22. Sosinsky, G. E. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9210-9214[Abstract]
  23. Kuraoka, A., Iida, H., Hatae, T., Shibata, Y., Itoh, M., and Kurita, T. (1993) J. Histochem. Cytochem. 41, 971-980[Abstract/Free Full Text]
  24. Bevans, C. G., and Harris, A. L. (1997) Biophys. J. 72, A272
  25. Bevans, C., and Harris, A. L. (1996) Biophys. J. 70, A32
  26. Bevans, C. G., and Harris, A. L. (1996) Mol. Biol. Cell 7, 281a
  27. Bevans, C. G., and Harris, A. L. (1995) Mol. Biol. Cell 6S, 190a
  28. Rhee, S. K., Bevans, C. G., and Harris, A. L. (1996) Biochemistry 35, 9212-9223[CrossRef][Medline] [Order article via Infotrieve]
  29. Bevans, C. G., Kordel, M., Rhee, S. K., and Harris, A. L. (1998) J. Biol. Chem. 273, 2808-2816[Abstract/Free Full Text]
  30. Goodenough, D. A., Paul, D. L., and Jesaitis, L. (1988) J. Cell Biol. 107, 1817-1824[Abstract]
  31. Mimms, L. T., Zampighi, G. A., Nozaki, Y., Tanford, C., and Reynolds, J. A. (1981) Biochemistry 20, 833-840[Medline] [Order article via Infotrieve]
  32. Harris, A. L., Walter, A., Paul, D. L., Goodenough, D. A., and Zimmerberg, J. (1992) Mol. Brain Res. 15, 269-280[Medline] [Order article via Infotrieve]
  33. Lehninger, A. L. (1974) Proc. Natl. Acad. Sci. U. S. A. 71, 1520-1524[Abstract]
  34. Harris, A. L., Walter, A., and Zimmerberg, J. (1989) J. Membr. Biol. 109, 243-250[Medline] [Order article via Infotrieve]
  35. Harris, A. L. (1994) in Biomembrane Electrochemistry (Blank, M., and Vodyanoy, I., eds), pp. 197-224, American Chemical Society, Washington, D. C.
  36. Harris, A. L., and Bevans, C. G. (1997) in Gap Junctions (Werner, R., ed), pp. 60-64, IOS Press, Amsterdam
  37. Sugawara, E., and Nikaido, H. (1994) J. Biol. Chem. 269, 17981-17987[Abstract/Free Full Text]
  38. Ikura, M., Clore, G. M., Gronenborn, A. M., Zhu, G., Klee, C. B., and Bax, A. (1992) Science 256, 632-638[Medline] [Order article via Infotrieve]
  39. Meador, W. E., Means, A. R., and Quiocho, F. A. (1992) Science 257, 1251-1255[Medline] [Order article via Infotrieve]
  40. Zhu, X., Zhao, X., Burkholder, W. F., Gragerov, A., Ogata, C. M., Gottesman, M. E., and Hendrickson, W. A. (1996) Science 272, 1606-1614[Abstract]
  41. Jia, Z., Barford, D., Flint, A. J., and Tonks, N. K. (1995) Science 268, 1754-1758[Medline] [Order article via Infotrieve]
  42. Joseph, D., Petsko, G. A., and Karplus, M. (1990) Science 249, 1425-1428[Medline] [Order article via Infotrieve]
  43. Wierenga, R. K., Borchert, T. V., and Noble, M. E. M. (1992) FEBS Lett. 307, 34-39[CrossRef][Medline] [Order article via Infotrieve]
  44. Sadegh-Nasseri, S., and McConnell, H. M. (1989) Nature 337, 274-276[CrossRef][Medline] [Order article via Infotrieve]
  45. Greene, L. E., Zinner, R., Naficy, S., and Eisenberg, E. (1995) J. Biol. Chem. 270, 2967-2973[Abstract/Free Full Text]
  46. Prasad, K., Heuser, J., Eisenberg, E., and Greene, L. (1994) J. Biol. Chem. 269, 6931-6939[Abstract/Free Full Text]
  47. Orlando, R. A., and Cheresh, D. A. (1991) J. Biol. Chem. 266, 19543-19550[Abstract/Free Full Text]
  48. Tsien, R. W., and Weingart, R. (1976) J. Physiol. (Lond) 260, 117-141[Abstract]
  49. Pitts, J. D., and Simms, J. W. (1977) Exp. Cell Res. 104, 153-163[CrossRef][Medline] [Order article via Infotrieve]
  50. Lawrence, T. S., Beers, W. H., and Gilula, N. B. (1978) Nature 272, 501-506[Medline] [Order article via Infotrieve]
  51. Murray, S. A., and Fletcher, W. H. (1984) J. Cell Biol. 98, 1710-1719[Abstract]
  52. Piccolino, M., Neyton, J., and Gerschenfeld, H. M. (1984) J. Neurosci. 4, 2477-2488[Abstract]
  53. Shabb, J. B., and Corbin, J. D. (1992) J. Biol. Chem. 267, 5723-5726[Free Full Text]
  54. Weber, I. T., Shabb, J. B., and Corbin, J. D. (1989) Biochemistry 28, 6122-6127[Medline] [Order article via Infotrieve]
  55. McAllister-Lucas, L. M., Haik, T. L., Colbran, J. L., Sonnenburg, W. K., Seger, D., Turko, I. V., Beavo, J. A., Francis, S. H., and Corbin, J. D. (1995) J. Biol. Chem. 270, 30671-30679[Abstract/Free Full Text]
  56. Johnson, R. L., Van Haastert, P. J. M., Kimmel, A. R., Saxe, C. L., Jastorff, B., and Devreotes, P. N. (1992) J. Biol. Chem. 267, 4600-4607[Abstract/Free Full Text]
  57. Van Haastert, P. J. M. (1995) Experientia 51, 1144-1154[Medline] [Order article via Infotrieve]
  58. Francis, S. H., Thomas, M. K., and Corbin, J. D. (1990) in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action (Beavo, J., and Houslay, M. D., eds), pp. 118-140, John Wiley and Sons, Ltd. Chichester
  59. Van Haastert, P. J. M., and Kien, E. (1983) J. Biol. Chem. 258, 9636-9642[Abstract/Free Full Text]
  60. Kim, J.-Y., and Devreotes, P. N. (1994) J. Biol. Chem. 269, 28724-28731[Abstract/Free Full Text]
  61. Kim, J.-Y., Caterina, M. J., Milne, J. L. S., Lin, K. C., Borleis, J. A., and Devreotes, P. N. (1997) J. Biol. Chem. 272, 2060-2068[Abstract/Free Full Text]
  62. Falk, M. M., Buehler, L. K., Kumar, N. M., and Gilula, N. B. (1997) EMBO J. 16, 2703-2716[Abstract/Free Full Text]
  63. Zhang, J. T., Chen, M. G., Foote, C. I., and Nicholson, B. J. (1996) Mol. Biol. Cell 7, 471-482[Abstract]
  64. Borel, A. C., and Simon, S. M. (1996) Cell 85, 379-389[Medline] [Order article via Infotrieve]
  65. Hanein, D., Matlack, K. E. S., Jungnickel, B., Plath, K., Kallies, K., Miller, K., Rapoport, T. A., and Akey, C. (1996) Cell 87, 721-732[Medline] [Order article via Infotrieve]
  66. Stopar, D., Spruijt, R. B., Wolfs, C. J., and Hemminga, M. A. (1996) Biochemistry 35, 15467-15473[CrossRef][Medline] [Order article via Infotrieve]
  67. Kálmán, L., Gajda, T., Sebban, P., and Maróti, P. (1997) Biochemistry 36, 4489-4496[CrossRef][Medline] [Order article via Infotrieve]
  68. Spruijt, R. B., Wolfs, C. J., Verver, J. W., and Hemminga, M. A. (1996) Biochemistry 35, 10383-10391[CrossRef][Medline] [Order article via Infotrieve]
  69. Stopar, D., Spruijt, R. B., Wolfs, C. J., and Hemminga, M. A. (1997) Biochemistry 36, 12268-12275[CrossRef][Medline] [Order article via Infotrieve]
  70. Makino, S., Woolford, J. L., Jr., Tanford, C., and Webster, R. E. (1975) J. Biol. Chem. 250, 4327-4332[Abstract]
  71. Cavalieri, S. J., Goldthwait, D. A., and Neet, K. E. (1976) J. Mol. Biol. 102, 713-722[Medline] [Order article via Infotrieve]
  72. Yeager, M. J., and Gilula, N. B. (1992) J. Mol. Biol. 223, 929-948[Medline] [Order article via Infotrieve]
  73. North, R. A. (ed) (1994) Ligand- and Voltage-Gated Ion Channels, CRC Press, Boca Raton, FL
  74. Zanello, L. P., Aztiria, E., Antollini, S. S., and Barrantes, F. J. (1996) Biophys. J. 70, 2155-2164[Abstract]
  75. Reynolds, J. A. (1982) in Lipid-Protein Interactions (Jost, P. C., and Griffith, O. H., eds), pp. 193-224, John Wiley & Sons, New York
  76. Matthews, B. W. (1982) in Lipid-Protein Interactions (Jost, P. C., and Griffith, O. H., eds), pp. 1-23, John Wiley & Sons, New York
  77. Bastiaanse, E. M., Hold, K. M., and van der Laarse, A. (1997) Cardiovasc. Res. 33, 272-283[CrossRef][Medline] [Order article via Infotrieve]
  78. Ryan, S. E., Demers, C. N., Chew, J. P., and Baenziger, J. E. (1996) J. Biol. Chem. 271, 24590-24597[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.